Board of Directors

Eddy is an expert virologist with a career spanning over 40 years in both academia and industry. He has held senior positions in both the Wellcome Research Laboratories and GlaxoWellcome. In 2000, Eddy left GlaxoWellcome to join his first biotech company becoming Senior Director at Medivir AB where he led the UK site and also Lead Discovery in both Sweden and the UK. At Medivir, he was part of several out-licensing deals with a total value of over $360m. He led the team that developed Olysio which was licensed to Janssen for the treatment of hepatitis C virus which had peak sales of over $10B.

Eddy became the Chief Executive Officer of Domainex in May 2008 where he helped develop the Company to become one of the UK’s leading drug discovery CROs. Under his leadership, Domainex also developed a pipeline of drugs aimed at inflammation and cancer.

In October 2016 Eddy joined ReViral, initially as CEO, leading a series B fund raise of $55m in June 2018. In 2019 he became the COO of ReViral as the Company moved into Phase 2 development. Eddy became Non-Executive Chairman of Domainex in June 2020.

Dr. Hayley French is an accomplished commercial leader and qualified attorney with over 25 years’ experience across the life science industry. Prior to joining Domainex, Hayley was Chief Executive Officer of Apitope Technology NV which was acquired by Worg Pharmaceuticals in September 2021. Before joining Apitope, Hayley spent three years at Novartis, based at the Basel headquarters, where she worked closely on all global deals and collaborations in the respiratory division.

She has also worked in the Life Sciences Group of Bird & Bird, London, specialising in advising pharmaceutical and biotech companies and as Head of Commercial Legal Affairs at the Centre for Applied Microbiology and Research (CAMR) in Salisbury, UK. 

Hayley started her career at University College London Ventures where she was responsible for the development, management and commercialisation of technologies in the life sciences sector. She is past president of the Licensing Executives Society Britain & Ireland, and a past board member of Licensing Executives Society International (LESI).

Hayley has a B.Sc. in Microbiology from the University of Liverpool, as well as a PhD in Microbiology and a M.Sc. in intellectual property from the University of London and is a certified licensing professional (CLP).

Hayley is also a venture partner for Vesalius Biocapital and chair of Octiocor Limited.

Laurence Pearl is Professor of Structural Biology at the University of Sussex. His laboratory studies the structural biology of DNA repair, signal transduction and molecular chaperones. Laurence is also Head of the Division of Structural Biology at the Institute of Cancer Research.

Laurence began his research career at Birkbeck College working with Prof Sir Tom Blundell, and after postdoctoral research at the Institute of Cancer Research Laboratories in Sutton, started his own laboratory at UCL in 1989, becoming Professor of Structural Biology in 1996. He joined the Institute of Cancer Research Chester Beatty Laboratories in Chelsea in 1999 where he became Professor of Crystallography and Chairman of the Section of Structural Biology. From 2009-2017 he was Head of the School of Life Sciences at the University of Sussex, relocating his laboratory to the MRC Genome Damage and Stability Centre, where he now holds the position of Professor of Structural Biology.

He is a Fellow of the Royal Society, an elected member of EMBO, a Fellow of the Academy of Medical Sciences, and a scientific advisor to Abingworth.

Edward Beckett is managing partner at Longbow Capital LLP, a leading private investor in UK based emerging companies across the life-sciences and well-being sectors.  

With over 20 years of experience investing in and building early stage technology ventures, Edward has been directly involved with the portfolio management and financing of more than 25 companies, including spin-outs from large corporates, universities and other research based organisations, taking more than half of them through to IPOs and trade sales.

Longbow Capital is focussed on supporting the scaling-up of its portfolio companies to become leaders in their respective categories.  Edward is a non-executive director on the Boards of Domainex Ltd and iPulse Ltd, representing Longbow’s private client investors and co-investors.

In an industrial career spanning 35 years, Dr Trevor Perrior has led drug discovery teams that have delivered numerous development candidates across several therapeutic areas. Following his education at the University of Cambridge Trevor undertook academic research at Cambridge, Oxford and in the USA. He then held a number of senior R&D leadership roles in the pharmaceutical and biotechnology companies ICI, Zeneca, AstraZeneca and Celltech, where he worked on sites in the UK, USA, and Switzerland.

In 2005 Trevor joined NCE Discovery as Chief Scientific Officer, and when NCE Discovery merged with Domainex he became Director of Research for the enlarged company. In 2016 he was appointed Chief Scientific Officer of Domainex, and then in 2018 Chief Executive Officer. In April 2020, Trevor retired from this role, but continues to support Domainex as a scientific consultant. Trevor is also a scientific consultant to a number of venture capital and charitable funds.